Your browser doesn't support javascript.
loading
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Kilian, Michael; Sheinin, Ron; Tan, Chin Leng; Friedrich, Mirco; Krämer, Christopher; Kaminitz, Ayelet; Sanghvi, Khwab; Lindner, Katharina; Chih, Yu-Chan; Cichon, Frederik; Richter, Benjamin; Jung, Stefanie; Jähne, Kristine; Ratliff, Miriam; Prins, Robert M; Etminan, Nima; von Deimling, Andreas; Wick, Wolfgang; Madi, Asaf; Bunse, Lukas; Platten, Michael.
Affiliation
  • Kilian M; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Sheinin R; Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Blavatnik School of Computer Science, Tel Aviv University, 69978 Tel Aviv, Israel.
  • Tan CL; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Ge
  • Friedrich M; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelb
  • Krämer C; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kaminitz A; Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Sanghvi K; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Ge
  • Lindner K; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany; Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Chih YC; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Ge
  • Cichon F; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Richter B; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jung S; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jähne K; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ratliff M; Department of Neurosurgery, University Hospital Mannheim, Mannheim, Germany.
  • Prins RM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Etminan N; Department of Neurosurgery, University Hospital Mannheim, Mannheim, Germany.
  • von Deimling A; DKTK CCU Neuropathology, DKFZ, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Wick W; Neurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany; DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany.
  • Madi A; Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: asafmadi@tauex.tau.ac.il.
  • Bunse L; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: l.bunse@dkfz.de.
  • Platten M; DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Immune Monitoring Unit, National Center for Tumor Diseases (N
Cancer Cell ; 41(2): 235-251.e9, 2023 02 13.
Article in En | MEDLINE | ID: mdl-36638785
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / T-Lymphocytes, Cytotoxic Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Alemania Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / T-Lymphocytes, Cytotoxic Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Alemania Country of publication: Estados Unidos